 |
|
|
| |
Prevalence of Archived HIV-1 DNA Resistance-associated Mutations and their Lack of Effect on Virologic Outcome at
Week 96 in Antiretroviral Treatment-experienced, Virologically Suppressed Patients Receiving the Once-daily, Single-tablet
Regimen Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in the EMERALD Phase III Trial
|
| |
| |
Presented at the 17th European AIDS Conference, Basel, Switzerland, November 6-9, 2019
Reported by Jules Levin
Erkki Lathouwers,1 Shirley Murrow,2 Bryan Baugh,3 Anne Ghys,1 John Jezorwski,4 El Ghazi Mohsine,1 Magda Opsomer,1 Sandra De Meyer1
1Janssen Pharmaceutica NV, Beerse, Belgium; 2Janssen Scientific Affairs, LLC, Titusville, NJ, USA; 3Janssen Research & Development LLC, Raritan, NJ, USA; 4Janssen Research & Development, Pennington, NJ, USA
|
| |
|
|
|
|
|
